Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.

1. World Health Organization
2. Risk-Benefit Balance
3. Development Safety Update Report
4. PV Agreement
5. Healthcare Professional
6. Clinical Trial Application
7. BeiGene Representative
8. Non-Interventional Study
9. Side effect
10. Sponsor
11. Tolerability
12. Special Situations
13. Important Potential Risks
14. Product Safety Strategy
15. Post-Marketing Surveillance
16. Safety Management Team
17. Adverse Event of Special Interest (AESI)
18. Occupational exposure
19. Good Pharmacovigilance Practice
20. process excellence
21. Other Safety Issue
22. Aggregate Safety Report (ASR)
23. Periodic Safety Update Report
24. Medicines and Healthcare Regulatory Agency
25. Pharmacovigilance
26. Company Core Data Sheet
27. Local Safety Representative
28. Signal Validation
29. Literature Report
30. Labeled or unlabeled
31. Clinical Development Program
32. Product Recall
33. Business Partner
34. New Drug Application
35. Pharmacoepidemiology
36. Good Clinical Practice
37. Drug Substance
38. Expectedness
39. Drug Abuse
40. Blinding or Masking
41. Pharmacovigilance
42. EudraVigilance
43. Periodic Benefit-Risk Evaluation Report
44. Monitoring Plan
45. Safety Assessment Team
46. Regulatory authority
47. Pharmacovigilance System
48. Council for International Organizations of Medical Sciences
49. Informed Consent
50. Non-serious AESI
51. Signal Assessment
52. Signal Detection Plan
53. GVP Module I
54. Signal Prioritization
55. Corrective and Preventive Action (CAPA)
56. Adverse Event Report Number
57. Dear Investigator Letter
58. Marketing Authorization Holder
59. Organized Data Collection Program
60. Company Core Safety Information
61. Urgent Safety Measure
62. Interventional Study
63. Data Lock Point
64. Global Patient Safety
65. Overdose
66. Investigational Medicinal Product
67. Investigator
68. Developmental Risk Management Plan
69. Observational study
70. Safety Signal
71. Contract Research Organization (CRO)
72. Safety Data Exchange Agreement
73. Clinical Study
74. National Medical Product Administration
75. Product
76. Medical Review
77. alliance management
78. background rates
79. Signal Management Process
80. Listedness/ expectedness
81. Refuted Signal
82. Investigator’s Brochure
83. Individual Case Safety Report (ICSR)
84. periodic safety update report (PSUR)
85. Spontaneous (Unsolicited) report
86. Drug Product
87. Patient Safety
88. Investigational New Drug Application
89. Non-validated signal
90. Comparator Product
91. Clinical Trial
92. Risk Management
93. Risk Management Plan
94. Global Safety Database
95. Validated Signal
96. Product Quality Complaint
97. Health Authority
98. Business Continuity Plan
99. Affiliate
100. Medical Dictionary for Regulatory Activities (MedRA)
101. Suspected Unexpected Serious Adverse Reaction (SUSAR)
102. Institutional Review Board
103. Causality Assessment
104. Unexpected Events
105. Quality Management System (QMS)
106. Qualified Person for Pharmacovigilance
107. Reference Safety Information
108. Quality Assurance
109. Identified Risk
110. Subject Matter Expert
111. Adverse Event (AE)
112. Risk Communication
113. Serious Adverse Event
114. International Conference on Harmonization (ICH)
115. Clinical Study Number
116. Country Safety Lead/Manager
117. Protocol
118. Signal Detection
119. Benefit-risk analysis
120. Post-authorization Safety Study
121. Individual Case Safety Report
122. Development International Birth Date
123. Drug Adverse Event Reporting System
124. Off-label use
125. Solicited reports
126. Company Safety Committee
127. Adverse Drug Reaction (ADR)
128. Safety Information
129. Chief Safety Officer
130. Pharmacovigilance System Master File